Immunome, Inc.

Immunome, Inc. is a clinical-stage biotechnology company focused on developing novel targeted therapies for cancer. The company's core strategy revolves around identifying and developing highly specific drug candidates that address unmet medical needs in oncology. Its lead clinical asset, Varegacestat, is a gamma secretase inhibitor currently undergoing Phase 3 clinical trials for the treatment of desmoid tumors, a rare and aggressive form of soft tissue cancer. Complementing this, Immunome is advancing IM-1021, an antibody-drug conjugate (ADC) targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1), which is in Phase 1 clinical development. The company's pipeline also includes promising preclinical assets such as IM-3050, a fibroblast activation protein (FAP)-targeted radioligand therapy, and a series of other solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome leverages its proprietary platform to discover and develop these innovative treatments, aiming to offer new therapeutic options for patients with difficult-to-treat cancers. The company's focus on targeted mechanisms and advanced drug modalities like ADCs positions it within a rapidly evolving and competitive biotechnology landscape, seeking to translate scientific breakthroughs into meaningful clinical outcomes.